ROSEN, A TOP-RANKED FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk securities between November 2, 2022, and December 19, 2024, about the upcoming lead plaintiff deadline of March 25, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Novo Nordisk securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by March 25, 2025 [2]. - The lawsuit claims that during the class period, defendants made misleading statements regarding the phase 3 CagriSema study on obesity, particularly about the expected outcomes and the trial protocol [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Investors have the option to select their counsel or remain absent from the class without affecting their ability to share in any potential recovery [6].